These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 30238558)

  • 21. Cost-effectiveness analysis of lifestyle intervention in obese infertile women.
    van Oers AM; Mutsaerts MAQ; Burggraaff JM; Kuchenbecker WKH; Perquin DAM; Koks CAM; van Golde R; Kaaijk EM; Schierbeek JM; Klijn NF; van Kasteren YM; Land JA; Mol BWJ; Hoek A; Groen H;
    Hum Reprod; 2017 Jul; 32(7):1418-1426. PubMed ID: 28486704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
    De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
    PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
    Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
    Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is cost effectiveness sustained after weekend inpatient rehabilitation? 12 month follow up from a randomized controlled trial.
    Brusco NK; Watts JJ; Shields N; Taylor NF
    BMC Health Serv Res; 2015 Apr; 15():165. PubMed ID: 25927870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of lumbar discectomy and single-level fusion for spondylolisthesis: experience with the NeuroPoint-SD registry.
    Mummaneni PV; Whitmore RG; Curran JN; Ziewacz JE; Wadhwa R; Shaffrey CI; Asher AL; Heary RF; Cheng JS; Hurlbert RJ; Douglas AF; Smith JS; Malhotra NR; Dante SJ; Magge SN; Kaiser MG; Abbed KM; Resnick DK; Ghogawala Z
    Neurosurg Focus; 2014 Jun; 36(6):E3. PubMed ID: 24881635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline.
    Ladhani SN; Fernandes S; Garg M; Borrow R; de Lusignan S; Bolton-Maggs PHB;
    Br J Haematol; 2024 May; 204(5):1672-1686. PubMed ID: 38600782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention.
    Karnon J; Afzali HHA; Putro GVAA; Thant PW; Dompok A; Cox I; Chikhwaza OH; Wang X; Mwangangi MM; Farransahat M; Cameron I
    Appl Health Econ Health Policy; 2017 Oct; 15(5):635-645. PubMed ID: 28349499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
    van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
    Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
    Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
    Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spleen Registry: Still a Chimera.
    Di Sabatino A; Lenti MV; Corazza GR
    Clin Infect Dis; 2018 Aug; 67(4):562-563. PubMed ID: 29471353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.